Investor Relations

Latest News

Cantabio Pharmaceuticals to Present Positive in vivo Efficacy Data in a Mice Model of Parkinson’s disease from Its DJ-1 Protein Targeting Therapeutic Program at the Neuro4D Conference in Mainz, Germany

Read Press Release

Latest Financial Results

Q3 2018

Quarterly Results

Ended Dec 31, 2017

Stock Information

Price Loading...
Change Loading...
Day Range Loading...
52 Wk Range Loading...

Investor Relations

IR Firm
Russo Partners LLC
Toll Free helpline: (844) 200-CTBO

Please be advised that the Corporate and Investor Relations personnel are not licensed for the sale or purchase of our common stock, and their phone numbers should not be used for placing orders for any share purchases. You should contact your individual broker if you wish to discuss your investment options and decisions.

Company Overview

Cantabio Pharmaceuticals Inc. is a preclinical stage biotechnology company focussing on commercializing novel therapies and the intellectual property generated from our research and development activities for Parkinson’s disease (PD), Alzheimer’s disease (AD) and other related neurodegenerative diseases.

Blue Sky Exemption


Cantabio Pharmaceuticals is listed in Mergent Manuals and News Reports™ and the company’s data, as well as news and financial statements, are accessible via Mergent’s online and print products. The Mergent Industrial Manual and News Reports™ is a recognized securities manual in 39 states for purposes of Blue Sky Manual Exemption. The company’s listing and further information is available here: